GlassScriptPhysician profile
Halim Fadil
NPI 1982814570
$12,724.86
in general payments reported to CMS, 2019-2025
59 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,264 · 2020: $1,449 · 2021: $2,241 · 2022: $2,343 · 2023: $1,577 · 2024: $2,016 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,369 · Education: $57.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,369.28 |
| Education | $57.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,059.20 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,051.11 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $1,019.51 | 2019-2025 | Nuplazid |
| Abbvie INC. | $945.97 | 2019-2025 | |
| Biogen, INC. | $698.66 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $603.23 | 2019-2025 | Rystiggo, Briviact |
| Neurocrine Biosciences, INC. | $512.51 | 2019-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $444.76 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Kyowa Kirin, INC. | $405.51 | 2020-2025 | Nourianz |
| Mdd US Operations, LLC | $345.13 | 2019-2025 | Gocovri, Gocovri |
| Boston Scientific Corporation | $344.34 | 2019-2025 | General - Dbs, Vercise |
| Amgen INC. | $310.16 | 2020-2025 | Uplizna |
| Acorda Therapeutics, INC | $301.14 | 2019-2024 | Inbrija, Ampyra |
| Lundbeck LLC | $287.88 | 2019-2025 | Vyepti, Rexulti |
| Adamas Pharmaceuticals, INC. | $265.63 | 2019-2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halim Fadil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.